Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVRNASDAQ:BMEANASDAQ:FBRXNASDAQ:RENB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$2.91+4.3%$6.08$7.96▼$24.15$14.68M0.6316,394 shs39,619 shsBMEABiomea Fusion$1.39-2.1%$1.87$1.29▼$13.07$52.23M-0.07908,601 shs767,390 shsFBRXForte Biosciences$9.67-16.1%$7.04$4.11▼$28.68$63.66M2.82157,681 shs172,365 shsRENBRenovaro$0.31-1.7%$0.39$0.28▼$2.34$54.17M0.621.02 million shs735,466 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir+4.30%-12.61%-56.57%-69.40%-83.24%BMEABiomea Fusion-2.11%-4.14%-37.95%-50.27%-88.07%FBRXForte Biosciences-16.13%+36.01%+35.81%+3.98%+37,035.18%RENBRenovaro-1.66%+8.82%-13.50%-68.69%-78.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALVRAlloVirN/AN/AN/AN/AN/AN/AN/AN/ABMEABiomea Fusion2.406 of 5 stars3.50.00.00.02.03.31.3FBRXForte Biosciences3.1034 of 5 stars3.53.00.00.03.41.71.3RENBRenovaro1.3905 of 5 stars0.03.00.00.02.63.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVRAlloVir 0.00N/AN/AN/ABMEABiomea Fusion 3.08Buy$22.601,525.90% UpsideFBRXForte Biosciences 3.00Buy$32.50236.09% UpsideRENBRenovaro 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ALVR, RENB, FBRX, and BMEA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.005/6/2025BMEABiomea FusionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $18.005/6/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/2/2025BMEABiomea FusionBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$11.00 ➝ $3.004/1/2025FBRXForte BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $61.003/31/2025BMEABiomea FusionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.003/24/2025BMEABiomea FusionOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$10.003/24/2025BMEABiomea FusionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.003/19/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/ABMEABiomea FusionN/AN/AN/AN/A$4.74 per shareN/AFBRXForte BiosciencesN/AN/AN/AN/A$24.30 per shareN/ARENBRenovaroN/AN/AN/AN/A$0.52 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%8/7/2025 (Estimated)BMEABiomea Fusion-$117.25M-$3.55N/AN/AN/AN/A-118.90%-93.66%7/30/2025 (Estimated)FBRXForte Biosciences-$31.48M-$16.29N/AN/AN/AN/A-151.43%-118.92%8/13/2025 (Estimated)RENBRenovaro-$80.65M-$0.77N/A∞N/AN/A-61.84%-48.07%N/ALatest ALVR, RENB, FBRX, and BMEA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025FBRXForte Biosciences-$0.89-$1.37-$0.48-$1.37N/AN/A5/5/2025Q1 2025BMEABiomea Fusion-$0.84-$0.80+$0.04-$0.80N/AN/A3/31/2025Q4 2024BMEABiomea Fusion-$1.00-$0.81+$0.19-$0.81N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/ABMEABiomea FusionN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/ARENBRenovaroN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78BMEABiomea FusionN/A3.393.39FBRXForte BiosciencesN/A2.062.06RENBRenovaroN/A0.060.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%BMEABiomea Fusion96.72%FBRXForte Biosciences77.63%RENBRenovaro71.41%Insider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%BMEABiomea Fusion27.57%FBRXForte Biosciences5.90%RENBRenovaro21.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionOptionableBMEABiomea Fusion5037.57 million26.25 millionOptionableFBRXForte Biosciences56.58 million6.20 millionOptionableRENBRenovaro20172.12 million124.24 millionOptionableALVR, RENB, FBRX, and BMEA HeadlinesRecent News About These CompaniesRenovaro Inc. Secures Ruling to Expedite Trial Against Predictive Oncology Over Breach of Merger AgreementMay 24, 2025 | nasdaq.comRenovaro Inc. Accelerates 2025 Lawsuit to Force Predictive Oncology MergerMay 22, 2025 | insidermonkey.comUPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive OncologyMay 22, 2025 | globenewswire.comRenovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive OncologyMay 22, 2025 | globenewswire.comRenovaro partners with Amsterdam UMC on cancer diagnosticsMay 15, 2025 | uk.investing.comRenovaro lanceert AI-platform voor versnelling neurologische medicijnontwikkelingMay 15, 2025 | nl.investing.comRenovaro Inc. and Amsterdam UMC Enter Exclusive Collaboration to Develop Blood Platelet RNA DiagnosticsMay 15, 2025 | nasdaq.comRenovaro launches AI platform to advance neurology drug discoveryMay 15, 2025 | investing.comRenovaro Launches Augusta, an AI-Powered Precision Neurology PlatformMay 14, 2025 | globenewswire.comRenovaro gaat samenwerking aan met Amsterdam UMC voor kankerdiagnostiekMay 13, 2025 | nl.investing.comRenovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA DiagnosticsMay 13, 2025 | globenewswire.comRenovaro Inc. (NASDAQ:RENB) Shares Acquired by Geode Capital Management LLCMay 2, 2025 | marketbeat.comRENB-aandeel raakt 52-weeks dieptepunt van $ 0,32 door marktuitdagingenMay 1, 2025 | nl.investing.comRenovaro BioSciences expands collaboration with NebulApril 23, 2025 | markets.businessinsider.comRenovaro Inc. Expands Collaboration with Nebul to Enhance Early Cancer Detection Through Advanced AI TechnologyApril 22, 2025 | quiverquant.comRenovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic ProgramsApril 22, 2025 | globenewswire.comRenovaro riskeert Nasdaq-notering te verliezen door te lage aandelenkoersApril 18, 2025 | nl.investing.comRenovaro BioSciences, BioSymetrics close merger transactionApril 9, 2025 | markets.businessinsider.comRenovaro Inc: Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision MedicineApril 9, 2025 | finanznachrichten.deRenovaro fuseert met BioSymetrics voor AI-gedreven medicijnontwikkelingApril 9, 2025 | nl.investing.comRenovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision MedicineApril 9, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALVR, RENB, FBRX, and BMEA Company DescriptionsAlloVir NASDAQ:ALVR$2.91 +0.12 (+4.30%) As of 05/27/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Biomea Fusion NASDAQ:BMEA$1.39 -0.03 (-2.11%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$1.39 0.00 (-0.07%) As of 05/28/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Forte Biosciences NASDAQ:FBRX$9.67 -1.86 (-16.13%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$8.98 -0.69 (-7.08%) As of 05/28/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Renovaro NASDAQ:RENB$0.31 -0.01 (-1.66%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$0.31 0.00 (-0.22%) As of 05/28/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
